ATE277012T1 - Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress - Google Patents

Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Info

Publication number
ATE277012T1
ATE277012T1 AT99945671T AT99945671T ATE277012T1 AT E277012 T1 ATE277012 T1 AT E277012T1 AT 99945671 T AT99945671 T AT 99945671T AT 99945671 T AT99945671 T AT 99945671T AT E277012 T1 ATE277012 T1 AT E277012T1
Authority
AT
Austria
Prior art keywords
treatment
donor
stress
piperidine
nitrogen oxide
Prior art date
Application number
AT99945671T
Other languages
German (de)
English (en)
Inventor
Erik Emil Aenggard
Abdullah Ibrahim Haj-Yehia
Original Assignee
Oxon Medica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxon Medica Inc filed Critical Oxon Medica Inc
Application granted granted Critical
Publication of ATE277012T1 publication Critical patent/ATE277012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99945671T 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress ATE277012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds
PCT/GB1999/000231 WO1999037616A1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress

Publications (1)

Publication Number Publication Date
ATE277012T1 true ATE277012T1 (de) 2004-10-15

Family

ID=10825732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99945671T ATE277012T1 (de) 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Country Status (9)

Country Link
US (3) US6448267B1 (enExample)
EP (1) EP1124801B1 (enExample)
JP (1) JP2002501049A (enExample)
AT (1) ATE277012T1 (enExample)
AU (1) AU4120699A (enExample)
CA (1) CA2318208C (enExample)
DE (1) DE69920496T2 (enExample)
GB (1) GB9801398D0 (enExample)
WO (1) WO1999037616A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
GB2349385A (en) * 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
KR20010038797A (ko) * 1999-10-27 2001-05-15 김길환 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
UY26893A1 (es) * 2000-08-22 2002-03-22 Boehringer Ingelheim Pharma Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20020151431A1 (en) * 2001-01-26 2002-10-17 Jeff Thornton Recovery method
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20030045461A1 (en) 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
WO2003053425A1 (en) * 2001-12-10 2003-07-03 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20060264408A1 (en) * 2003-03-06 2006-11-23 Haj-Yehia Abdullah I Sod minic multifunctional compounds for treating inflammatory bowel disease
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
EP1766014A4 (en) 2004-06-03 2008-12-10 Athlomics Pty Ltd AGENTS AND METHODS FOR THE DIAGNOSIS OF STRESS
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1883614A4 (en) * 2005-05-23 2010-04-14 Nicox Sa ORGANIC NITRIC OXIDES IMPROVING SALTS FROM NON-SUBSTITUTE INFLAMMATORY COMPOUNDS AND COMPOSITIONS AND USES THEREOF
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
AU2006343591A1 (en) * 2006-05-11 2007-11-22 Bell Helicopter Textron, Inc. Device and method for repairing structural components
US20090311189A1 (en) * 2006-05-12 2009-12-17 Massachusetts Institute Of Technology Temperature-jump dynamic nuclear polarization
US7985594B2 (en) * 2006-05-12 2011-07-26 Massachusetts Institute Of Technology Biradical polarizing agents for dynamic nuclear polarization
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
JP5191702B2 (ja) * 2006-08-01 2013-05-08 三菱レイヨン株式会社 Ｎ−オキシル化合物、その製造方法および重合防止方法
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
EP2418945B1 (en) 2009-04-15 2018-12-05 BMG PHARMA S.p.A. Mineral salt-sulfonic acid compositions and methods of use
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8715621B2 (en) 2012-03-15 2014-05-06 Massachusetts Institute Of Technology Radical polarizing agents for dynamic nuclear polarization
WO2013190497A2 (en) 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
PT2964218T (pt) 2013-03-05 2018-03-26 Radikal Therapeutics Inc Pró-fármacos de derivados de nitróxido multifuncional e utilizações dos mesmos
WO2016151591A1 (en) * 2015-03-26 2016-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nitroxide radicals for the treatment of diseases of the respiratory tract
CA3204594A1 (en) 2020-12-15 2022-06-23 Life Technologies Corporation Chemically defined serum albumin substitutes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752812A (en) 1970-02-05 1973-08-14 Pfizer 2-trifluoromethylquinoxalinedi n oxides
US4563446A (en) 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3328365A1 (de) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Neue diagnostische mittel
US5352442A (en) 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5890387A (en) 1989-08-24 1999-04-06 Aquaform Inc. Apparatus and method for forming and hydropiercing a tubular frame member
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
JP3775796B2 (ja) 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US6140309A (en) 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5885842A (en) 1996-11-08 1999-03-23 Medinox, Inc. Methods for the detection of nitric oxide in fluid media
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
JP3377731B2 (ja) * 1997-09-29 2003-02-17 三菱重工業株式会社 高性能水素分離膜
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
CA2352144A1 (en) 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
US6395736B1 (en) 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU781084B2 (en) 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide

Also Published As

Publication number Publication date
GB9801398D0 (en) 1998-03-18
WO1999037616A1 (en) 1999-07-29
DE69920496T2 (de) 2005-08-25
AU4120699A (en) 1999-08-09
CA2318208C (en) 2009-09-29
US20030069429A1 (en) 2003-04-10
CA2318208A1 (en) 1999-07-29
JP2002501049A (ja) 2002-01-15
US6759430B2 (en) 2004-07-06
US6448267B1 (en) 2002-09-10
DE69920496D1 (de) 2004-10-28
EP1124801A1 (en) 2001-08-22
US6455542B1 (en) 2002-09-24
EP1124801B1 (en) 2004-09-22
US20020091266A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
DE69920496D1 (de) Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
MY119820A (en) Guanidine mimics as factor xa inhibitors
PE74399A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
AP2003002841A0 (en) Quinazolines as MMP-13 inhibitors
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
ATE229001T1 (de) Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
UA35574C2 (uk) Похідні заміщеної гетероциклом фенілциклогексанкарбонової кислоти, суміші їх ізомерів або окремі ізомери та їх солі
TR199901765T2 (xx) S�lfomid-metalloproteaz inhibit�rleri
DE69313051D1 (de) Ethanolamin-derivate mit sympathomimetischer und anti-pollakiuria wirkung
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
DE69526917D1 (de) Anthracyclinon-derivate und ihre verwendung in amyloidose
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
EP1375496A4 (en) N-ARYL SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICAMENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT
NO982505L (no) Sammensetning og fremgangsmÕte for avsvovling av gassformige eller flytende hydrokarboner, vandige systemer og blandinger derav
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DE69119282D1 (de) Aminobenzolverbindungen, Herstellung und Verwendung
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
ATE95815T1 (de) Mittel zum schutz von pflanzen gegen krankheiten.
EA200001107A1 (ru) ПРОИЗВОДНЫЕ ОКТАГИДРО-6,10-ДИОКСО-6H-ПИРИДАЗИНО [1,2-a] [1,2] ДИАЗЕПИН-1-КАРБОНОВОЙ КИСЛОТЫ, СПОСОБ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТЕРАПЕВТИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties